TY - JOUR
T1 - Proteínas pro-apoptóticas y anti-apoptóticas como factores de pronóstico en Linfoma B difuso de célula grande en adultos
AU - Martín-Reyes, Liliana
AU - Quijano-Gómez, Sandra
AU - Bravo-Hernández, María Mercedes
PY - 2010/7
Y1 - 2010/7
N2 - Objective: Our purpose was to evaluate the expression of antiapoptotic proteins Bcl-2 and Bcl-x L, and pro-apoptotic proteins Bad and Bax and their association with survival, in patients with DLBCL. Materials and methods: We analyzed biopsies from 28 patients diagnosed with DLBCL. The expression of the apoptotic regulators was assessed by western blot. The association between protein expression and survival was analyzed by the Kaplan-Meier method and the log-rank test. Results: Bcl-2, Bak, Bad and Bcl-xL proteins were expressed in 78.8, 71.4, 64.3 and 50% of the DLBCL cases, respectively. We found no association between the presence of proteins or their expression levels and overall survival. Both Bad and Bcl-xL were associated with higher disease-free survival (33.3% vs. 20.0%, p LR test= 0,003; 42.9% vs. 14.3%, p LR test= 0.03, respectively). High expression levels of Bad and Bcl-xL were associated with a higher disease-free survival (35.7% vs. 21.4%, p LR test= 0.012 y 42.9% vs. 14.3%, p LR test= 0.045, respectively). Conclusion: Given that expression of the Bad protein in tumors was related to a higher disease-free survival, patients with low expression levels of Bad could be candidates in future therapies oriented towards the inhibition of the anti-apoptotic proteins Bcl-xL and Bcl-2 by using molecules that bind specifically to the BH3 domain.
AB - Objective: Our purpose was to evaluate the expression of antiapoptotic proteins Bcl-2 and Bcl-x L, and pro-apoptotic proteins Bad and Bax and their association with survival, in patients with DLBCL. Materials and methods: We analyzed biopsies from 28 patients diagnosed with DLBCL. The expression of the apoptotic regulators was assessed by western blot. The association between protein expression and survival was analyzed by the Kaplan-Meier method and the log-rank test. Results: Bcl-2, Bak, Bad and Bcl-xL proteins were expressed in 78.8, 71.4, 64.3 and 50% of the DLBCL cases, respectively. We found no association between the presence of proteins or their expression levels and overall survival. Both Bad and Bcl-xL were associated with higher disease-free survival (33.3% vs. 20.0%, p LR test= 0,003; 42.9% vs. 14.3%, p LR test= 0.03, respectively). High expression levels of Bad and Bcl-xL were associated with a higher disease-free survival (35.7% vs. 21.4%, p LR test= 0.012 y 42.9% vs. 14.3%, p LR test= 0.045, respectively). Conclusion: Given that expression of the Bad protein in tumors was related to a higher disease-free survival, patients with low expression levels of Bad could be candidates in future therapies oriented towards the inhibition of the anti-apoptotic proteins Bcl-xL and Bcl-2 by using molecules that bind specifically to the BH3 domain.
KW - Bad protein
KW - Bax protein
KW - Bcl-2 protein
KW - Diffuse large B-cell lymphoma
KW - Survival analysis
UR - http://www.scopus.com/inward/record.url?scp=78650744558&partnerID=8YFLogxK
U2 - 10.11144/javeriana.sc15-3.paaa
DO - 10.11144/javeriana.sc15-3.paaa
M3 - Artículo
AN - SCOPUS:78650744558
SN - 0122-7483
VL - 15
SP - 240
EP - 250
JO - Universitas Scientiarum
JF - Universitas Scientiarum
IS - 3
ER -